Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Oxurion    OXUR   BE0003846632

OXURION

(OXUR)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
08/14/2019 08/15/2019 08/16/2019 08/19/2019 08/20/2019 Date
5.52(c) 5.43(c) 5.51(c) 5.57(c) 3.18 Last
300 870 157 888 77 414 65 574 1 470 062 Volume
-7.85% -1.63% +1.47% +1.09% -42.91% Change
More quotes
Financials (EUR)
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Finance 2019 40,0 M
Yield 2019 -
Sales 2020 -
EBIT 2020 -
Net income 2020 -
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 -
EV / Sales2019 -
EV / Sales2020 -
Capitalization 213 M
More Financials
Company
Oxurion (formerly ThromboGenics) specializes in the research and development of bio-therapeutic products for treating cardiovascular diseases, ophthalmic disorders, and cancers. Net sales break down by source of income as follows: - sales of products (86.1%); - royalties (13.9%). 
More about the company
Latest news on OXURION
06/11OXURION : ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipelin..
GL
06/06OXURION : NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlG..
GL
05/08OXURION NV : Oxurion NV Business Update - Q1 2019
GL
04/26OXURION : Bicycle Therapeutics and Oxurion Announce Full Enrollment in Phase I T..
AQ
04/26OXURION : to Present Further Preclinical Data at 2019 ARVO Meeting
PU
04/24OXURION : announces full enrollment in Phase 1 trial evaluating the safety of pl..
PU
04/05OXURION : announces full enrollment of its Phase 2 trial evaluating efficacy and..
AQ
04/04OXURION : announces full enrollment of its Phase 2 trial evaluating efficacy and..
PU
04/04OXURION : NV announces full enrollment of its Phase 2 trial evaluating efficacy ..
GL
03/07OXURION : Business Update - FY 2018
AQ
More news
Analyst Recommendations on OXURION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
08/07NOVARTIS : Medicare Moves to Cover Costly Cell Therapies
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart OXURION
Duration : Period :
Oxurion Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXURION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 6,00  €
Last Close Price 5,57  €
Spread / Highest target 7,72%
Spread / Average Target 7,72%
Spread / Lowest Target 7,72%
EPS Revisions
Managers
NameTitle
Patrik de Haes Chief Executive Officer & Executive Director
Thomas Moragne Clay Chairman
Dominique Vanfleteren Chief Financial Officer
Susan Schneider Chief Medical Officer
David R. Guyer Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
OXURION53.87%237
IQVIA HOLDINGS INC34.91%30 405
LONZA GROUP34.43%25 942
INCYTE CORPORATION32.91%17 876
CELLTRION, INC.--.--%16 305
EXACT SCIENCES CORPORATION89.89%15 515